BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026

Reuters12-18

BRIEF-Aprea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> CEO Issues Letter To Shareholders Highlighting Outlook For 2026

Dec 18 (Reuters) - Aprea Therapeutics Inc APRE.O:

APREA THERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING PIPELINE PROGRESS IN 2025 AND OUTLOOK FOR 2026
APREA THERAPEUTICS INC - PAUSES ENROLLMENT IN ABOYA-119 STUDY MONOTHERAPY ARMS

Source text: ID:nGNX1SSvv2

Further company coverage: APRE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592690723?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592690723","market":"fut","top_or_hot":-1,"title":"BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO Issues Letter To Shareholders Highlighting Outlook For 2026</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Aprea Therapeutics Inc <span>APRE.O</span>:</p><ul><li><p>APREA THERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING PIPELINE PROGRESS IN 2025 AND OUTLOOK FOR 2026</p></li><li><p>APREA THERAPEUTICS INC - PAUSES ENROLLMENT IN ABOYA-119 STUDY MONOTHERAPY ARMS</p></li></ul><p>Source text: <span>ID:nGNX1SSvv2</span></p><p>Further company coverage: <span>APRE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO Issues Letter To Shareholders Highlighting Outlook For 2026</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Aprea Therapeutics Inc <span>APRE.O</span>:</p><ul><li><p>APREA THERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING PIPELINE PROGRESS IN 2025 AND OUTLOOK FOR 2026</p></li><li><p>APREA THERAPEUTICS INC - PAUSES ENROLLMENT IN ABOYA-119 STUDY MONOTHERAPY ARMS</p></li></ul><p>Source text: <span>ID:nGNX1SSvv2</span></p><p>Further company coverage: <span>APRE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA65LQYL:1","article_id":"2592690723","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592690723","pubTimestamp":1766071065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026Dec 18 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APRE":"Aprea Therapeutics, Inc."},"translate_title":"简报-Aprea Therapeutics首席执行官致股东信，强调2026年前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APRE":0.9},"content_text":"BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026Dec 18 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING PIPELINE PROGRESS IN 2025 AND OUTLOOK FOR 2026APREA THERAPEUTICS INC - PAUSES ENROLLMENT IN ABOYA-119 STUDY MONOTHERAPY ARMSSource text: ID:nGNX1SSvv2Further company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592690723","isCrawlerRequest":true}